256 related articles for article (PubMed ID: 1819434)
1. [Acellular anti-pertussis vaccine].
Bégué P; Grimpel E; Baron S
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):859-65. PubMed ID: 1819434
[TBL] [Abstract][Full Text] [Related]
2. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
Rappuoli R
Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
[TBL] [Abstract][Full Text] [Related]
3. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
[TBL] [Abstract][Full Text] [Related]
4. Pertussis: persistent pathogen, imperfect vaccines.
Yeh SH
Expert Rev Vaccines; 2003 Feb; 2(1):113-27. PubMed ID: 12901603
[TBL] [Abstract][Full Text] [Related]
5. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
Blennow M; Granström M
Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
Gustafsson L; Hessel L; Storsaeter J; Olin P
Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
[TBL] [Abstract][Full Text] [Related]
7. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
Mallet E; Puyt A; Arson S; Surbled V
Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of pertussis and high expectations concerning vaccines].
Wysocki J
Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
[TBL] [Abstract][Full Text] [Related]
9. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
10. [Acellular pertussis vaccine].
Wiedermann G; Ambrosch F; Vanura H
Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
[TBL] [Abstract][Full Text] [Related]
11. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
[TBL] [Abstract][Full Text] [Related]
12. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
13. Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
Elomaa A; He Q; Minh NN; Mertsola J
Vaccine; 2009 Sep; 27(40):5443-9. PubMed ID: 19628060
[TBL] [Abstract][Full Text] [Related]
14. Pertussis vaccines: present status.
Christodoulides M
Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
Purdy KW; Hay JW; Botteman MF; Ward JI
Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
[TBL] [Abstract][Full Text] [Related]
17. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention.
Munoz FM
Semin Pediatr Infect Dis; 2006 Jan; 17(1):14-9. PubMed ID: 16522501
[TBL] [Abstract][Full Text] [Related]
18. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
19. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
20. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
